Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abicipar, accidental, acetonide, agonist, Alimera, allergy, anacetrapib, arthralgia, Atara, Australian, automatically, automation, Avalanche, Aventisub, backup, Baylor, Bispecific, Breakthrough, BSA, CETP, childbearing, CHMP, cholesterylester, classification, clearing, cloud, COMBO, concomitantly, concurrent, confidence, corticosteroid, CSwNP, CT, CV, CVD, Delaware, delineated, deliverable, description, dexamethasone, disagree, dismissing, disturbance, double, draining, drip, EASI, eczema, endoscopic, EoE, EPO, ESC, Esperion, EULAR, evacetrapib, explicit, extinguishment, fashion, FH, Fifty, float, fluocinolone, forfeiture, formulary, frame, franchise, Francisco, goodwill, Hague, hazard, hearing, herpeticum, hospitalization, hypercholesterolemic, IGA, Iluvien, image, immunosuppressant, implant, implicate, imposition, inadvertently, incremental, ingram, inhaled, intervened, intranasal, IPO, IRS, itching, Labour, League, ligament, loading, lot, LS, lymphopoietin, MAA, media, MHLW, Ministry, ml, molecular, MONARCH, municipal, musculoskeletal, myalgia, narrow, NDA, NME, nose, notified, novelty, NPS, NRS, numerically, obstruction, opthalmology, oropharyngeal, overdose, Ozurdex, pediatric, pegol, petitioned, Pfenex, pharmacy, Polyp, pool, Portability, postmarketing, postnasal, PRALUENT, PRALUENTTM, prejudice, preserve, principle, ratio, reacquisition, reassessed, reconsider, registry, reinstating, reliance, retrospectively, Rheumatism, Rheumatology, room, rosuvastatin, rosuvastatine, RSV, runny, San, scan, SCORAD, sense, served, Sick, skin, sleep, slower, smell, SOLO, sprain, spray, stromal, surgery, swallowing, syncytial, task, threshold, throughput, thymic, tissue, topline, TSLP, uncontrolled, unenforceable, University, upcoming, Utrecht, visit, voucher, Welfare, women
Removed:
accrual, agree, allocation, amortizing, BDNF, bevacizumab, breakdown, canceled, chemotherapy, Chugai, closely, collateral, collateralize, collateralized, computation, concept, conclusion, considerably, Convertase, damaged, deducting, default, defer, dispute, divided, eric, essential, experimental, expressed, functional, gave, inclusion, institutional, Kabushiki, Kaisha, kinase, leaky, leasehold, light, MedImmune, modify, multinational, novation, OncoMed, Onyx, ordered, positively, prepayment, proof, Proprotein, remodeling, repair, resolved, satisfaction, Seiyaku, sensitization, shooter, Society, solid, strongly, successor, suggesting, tocilizumab, UK, unamortized, upregulated, vessel, VIEW, withheld, withholding
Filing tables
Filing exhibits
- 10-K Annual report
- 10.10.1 Restated Amendment Agreement by and Between Bayer Healthcare and the Registrant
- 10.21.2 2ND Amendment Between Goldman Sachs and the Registrant
- 10.25.2 2ND Amendment Between Credit Suisse and the Registrant
- 10.25.3 3RD Amendment Between Credit Suisse and the Registrant
- 21.1 Subsidiaries of Regeneron Pharmaceuticals, Inc.
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
REGN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, and 333-198794) and on Form S‑3 (No. 333-192091) of Regeneron Pharmaceuticals, Inc., of our report dated February 12, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 12, 2015